Early antiretroviral treatment reduces risk of bacille Calmette- Guérin immune reconstitution adenitis
dc.contributor.author | Rabie H. | |
dc.contributor.author | Violari A. | |
dc.contributor.author | Duong T. | |
dc.contributor.author | Madhi S.A. | |
dc.contributor.author | Josipovic D. | |
dc.contributor.author | Innes S. | |
dc.contributor.author | Dobbels, Els | en_ZA |
dc.contributor.author | Lazarus E. | |
dc.contributor.author | Panchia R. | |
dc.contributor.author | Babiker A.G. | |
dc.contributor.author | Gibb D.M. | |
dc.contributor.author | Cotton M.F. | |
dc.date.accessioned | 2011-10-13T16:58:39Z | |
dc.date.available | 2011-10-13T16:58:39Z | |
dc.date.issued | 2011 | |
dc.description | Please help us populate SUNScholar with the post print version of this article. It can be e-mailed to: scholar@sun.ac.za | |
dc.description.abstract | SETTING: Two centres in Soweto and Cape Town, South Africa. OBJECTIVE: To assess the effects of timing of initiation of antiretroviral treatment (ART) and other factors on the risk of bacille Calmette-Guérin (BCG) related regional adenitis due to immune reconstitution infl ammatory syndrome (BCG-IRIS) in human immunodefi ciency virus (HIV) infected infants. DESIGN: HIV-infected infants aged 6-12 weeks with CD4 count ≥25% enrolled in the Children with HIV Early Antiretroviral Therapy (CHER) Trial received early (before 12 weeks) or deferred (after immunological or clinical progression) ART; infants with CD4 count <25% all received early ART. All received BCG vaccination after birth. Reactogenicity to BCG was assessed prospectively during routine study follow-up. RESULTS: Of 369 infants, 32 (8.7%) developed BCGIRIS within 6 months of starting ART, 28 (88%) within 2 months after ART initiation. Of the 32 cases, 30 (93.8%) had HIV-1 RNA > 750 000 copies/ml at initiation. Incidence of BCG-IRIS was 10.9 and 54.3 per 100 personyears (py) among infants with CD4 count ≥25% at enrolment receiving early (at median age 7.4 weeks) vs. deferred (23.2 weeks) ART, respectively (HR 0.24, 95%CI 0.11-0.53, P < 0.001). Infants with CD4 count <25% receiving early ART had intermediate incidence (41.7/ 100 py). Low CD4 counts and high HIV-1 RNA at initiation were the strongest independent risk factors for BCG-IRIS. CONCLUSIONS: Early ART initiation before immunological and/or clinical progression substantially reduces the risk of BCG-IRIS regional adenitis. © 2011 The Union. | |
dc.description.version | Article | |
dc.identifier.citation | International Journal of Tuberculosis and Lung Disease | |
dc.identifier.citation | 15 | |
dc.identifier.citation | 9 | |
dc.identifier.citation | http://www.scopus.com/inward/record.url?eid=2-s2.0-80051676494&partnerID=40&md5=6cd568cde5eaff63f01b473bf9c2245f | |
dc.identifier.issn | 10273719 | |
dc.identifier.other | 10.5588/ijtld.10.0721 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/16804 | |
dc.subject | BCG | |
dc.subject | Immune reconstitution infl ammatory syndrome | |
dc.subject | Paediatric HIV | |
dc.subject | antiretrovirus agent | |
dc.subject | BCG vaccine | |
dc.subject | virus RNA | |
dc.subject | article | |
dc.subject | BCG vaccination | |
dc.subject | CD4 lymphocyte count | |
dc.subject | controlled study | |
dc.subject | early intervention | |
dc.subject | female | |
dc.subject | human | |
dc.subject | Human immunodeficiency virus 1 | |
dc.subject | Human immunodeficiency virus infection | |
dc.subject | immune reconstitution inflammatory syndrome | |
dc.subject | infant | |
dc.subject | lymphadenitis | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | multicenter study | |
dc.subject | outcome assessment | |
dc.subject | priority journal | |
dc.subject | prospective study | |
dc.subject | risk assessment | |
dc.subject | risk factor | |
dc.subject | risk reduction | |
dc.subject | South Africa | |
dc.subject | treatment planning | |
dc.subject | virus load | |
dc.title | Early antiretroviral treatment reduces risk of bacille Calmette- Guérin immune reconstitution adenitis | |
dc.type | Article |